Activity Date: 04/26/2022
Clinical consequences associated with uncontrolled symptoms of schizophrenia present treatment challenges and can increase disease burden for both patients and health care providers. Recognizing treatment challenges, including nonadherence to therapy or suboptimal therapy, and identifying potential strategies to improve adherence are essential to prevent disease relapse and improve overall patient outcomes. Pharmacists have an important role in the treatment of schizophrenia by helping to choose initial therapy according to patient-specific factors, addressing suboptimal therapeutic responses, and mitigating adverse effects. The current treatment landscape of schizophrenia continues to evolve with novel therapies and routes of administration, offering pharmacists more opportunities to make treatment interventions to improve patients’ symptom control, improve adherence, and address treatment-related challenges. This program will review updated clinical guidelines, efficacy and safety of newer treatment strategies, and considerations for their administration in both inpatient and outpatient clinical practice settings.
HOW TO RECEIVE CREDIT
Please follow the below instructions to claim your credit:
NOTE: Participation data will not be uploaded into CPE Monitor if you do not have your NABP (e-profile ID) number and date of birth entered in your profile.
All participants must request credit by July 26, 2022.
Megan Maroney, PharmD, BCPPView biographical information and disclosures
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.